| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2023 | ACCURIUS THERAPEUTICS, INC. | 213 EAST ST | LEXINGTON | MA | 02420-1924 | MIDDLESEX | USA | R44CA287806 | Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV) | 000 | 1 | NIH | 3/18/2025 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $1,000,000 ) |
| | 2024 | 2024 | ACCURIUS THERAPEUTICS, INC. | 213 EAST ST | LEXINGTON | MA | 02420-1924 | MIDDLESEX | USA | R44CA287806 | Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV) | 002 | 2 | NIH | 9/4/2024 | $1,000,000 |
| | 2024 | 2023 | ACCURIUS THERAPEUTICS, INC. | 213 EAST ST | LEXINGTON | MA | 02420-1924 | MIDDLESEX | USA | R44CA287806 | Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV) | 001 | 1 | NIH | 9/4/2024 | $0 |
| | 2024 | 2023 | ACCURIUS THERAPEUTICS, INC. | 213 EAST ST | LEXINGTON | MA | 02420-1924 | MIDDLESEX | USA | R44CA287806 | Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV) | 000 | 1 | NIH | 11/13/2023 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $399,999 ) |
| | 2023 | 2023 | ACCURIUS THERAPEUTICS, INC. | 213 EAST ST | LEXINGTON | MA | 02420-1924 | MIDDLESEX | USA | R44CA287806 | Preclinical and IND enabling studies for treatment of advanced lung cancer and other cancers metastatic to lung by pulmonary delivery of engineered Influenza A Virus (eIAV) | 000 | 1 | NIH | 9/21/2023 | $399,999 |
|
|
